NorthWest Biotherapeutics Inc (NWBO)

[Smokey21]

I believe that Larry has a couple of errors in his article.

Overall in the trial 90% or more of patients received DCVax-L indicating that 76 or more of the patients who started on SOC were crossed over to DCVax-L and that only 34 or less patients in the trial received only DCVax-L

I believe he meant to say 34 or less received only SOC.

NWBO has decided to let the trial continue in order to have a clear insight into the survival tail. In this trial of 331 patients, the median time of enrollment was May of 2014 and the last patient was enrolled in November of 2014. This means that even the last person enrolled will have three year survival data when the trial is stopped and the data analyzed and most will have far more.

I believe the last patient was enrolled in November, 2015